Clinical Trial Update: BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating BCL-2 inhibitors in combination with the HyperCVAD regimen for newly diagnosed T-cell lymphoblastic leukemia/lymphoma is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoblastic Lymphoma
• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• BCL-2 inhibitors

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Lymphoblastic Lymphoma, Adult, Lymphoblastic Leukemia, Acute T-cell | Phase 2 | Status: RECRUITING